Morgan Stanley Reiterates Equal-Weight Rating on Sagent Pharmaceuticals

In a report published Monday, Morgan Stanley reiterated its Equal-Weight rating on Sagent Pharmaceuticals

. Morgan Stanley noted, “Total November IMS sales were $17MM establishing a 4Q12 run rate of $53MM in-line with MSe and Cns of $52MM and guidance of ~$50MM. However, the focus is now on 2013 commercial momentum and we are comfortable with our $227MM estimate for 2013 (consensus of $243MM) driven by new launches and firming base business performance.” Sagent Pharmaceuticals closed on Friday at $15.70.